From the Black press
Community · Miami, FL

Servier Presents Updated Four-Year Results from Phase 2 FIREFLY-1 Study of OJEMDA® (tovorafenib) in Pediatric Low-Grade Glioma (pLGG) at SNO 2026

0 sent to miamitimesonline.com280 headlines carried

Updated longer-term analysis, including up to four years of follow-up data in patients with relapsed or refractory BRAF-altered pediatric low-grade glioma treated with OJEMDA®(tovorafenib), will be

Continue reading

The full story is at The Miami Times.

The Miami Times reported this story. TUEPAC carries the headline and opening so you can find it here; the reporting, photos, and readership stay with the publisher.

Continue at miamitimesonline.com ↗Opens the publisher's site
Stay on this

Follow what you care about and we send a weekly digest, every story linked to its publisher.

Headline and an excerpt of at most 40 words from the publisher's public feed. This page's canonical URL points to the original at miamitimesonline.com. How we carry publishers' work · Publisher: see your report